POLYPHOTONIX NOCTURA 500 MEDICAL DEVICE DEVELOPMENT

Lead Participant: POLYPHOTONIX LIMITED

Abstract

PolyPhotonix Ltd, an innovative UK SME, based in the North East of England will develop a
prototype light therapy sleep mask "Noctura 500" for the treatment of wet age related macular
degeneration (Wet AMD). The Noctura 500 concept results from earlier in-house R&D
activities in the area of Organic Light Emitting Diode (OLED) technology. Through
cooperation with clinical partners, PolyPhotonix will participate in early stage clinical trials to
show safety and proof of principle of the proposed device.
PolyPhotonix seek to provide a non-invasive, monitored but home-based treatment as an
alternative to the current intraocular injections received in a hospital environment for wet
AMD. The light therapy mask aims at prevention and halting disease progression; thus
maintaining eye health and visual acuity in an ageing population.

Lead Participant

Project Cost

Grant Offer

POLYPHOTONIX LIMITED £555,526 £ 249,986
 

Participant

CENTRE FOR PROCESS INNOVATION LIMITED

Publications

10 25 50